NGL Fine-Chem Limited (BOM:524774)
2,663.25
-57.00 (-2.10%)
At close: Sep 11, 2026
NGL Fine-Chem Revenue
NGL Fine-Chem had revenue of 1.39B INR in the quarter ending June 30, 2026, with 33.57% growth. This brings the company's revenue in the last twelve months to 5.36B, up 40.41% year-over-year. In the fiscal year ending March 31, 2026, NGL Fine-Chem had annual revenue of 5.01B with 36.03% growth.
Revenue (ttm)
5.36B
Revenue Growth
+40.41%
P/S Ratio
3.07
Revenue / Employee
10.76M
Employees
498
Market Cap
16.45B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 5.01B | 1.33B | 36.03% |
| Mar 31, 2025 | 3.68B | 295.68M | 8.73% |
| Mar 31, 2024 | 3.39B | 606.08M | 21.79% |
| Mar 31, 2023 | 2.78B | -394.22M | -12.42% |
| Mar 31, 2022 | 3.18B | 595.28M | 23.08% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 25.24B |
| Symbiotec Pharmalab | 8.69B |
| Bajaj HealthCare | 6.28B |
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Gujarat Themis Biosyn | 1.74B |
| Influx Healthtech | 1.47B |
| Smruthi Organics | 1.12B |
| Resonance Specialties | 1.02B |